Display options
Cite
Refaat T, West D, El Achy S, et al. Distribution of Iron Oxide Core-Titanium Dioxide Shell Nanoparticles in VX2 Tumor Bearing Rabbits Introduced by Two Different Delivery Modalities. Nanomaterials (Basel). 2016;6(8)doi: 10.3390/nano6080143.
Refaat, T., West, D., El Achy, S., Parimi, V., May, J., Xin, L., Harris, K. R., Liu, W., Wanzer, M. B., Finney, L., Maxey, E., Vogt, S., Omary, R. A., Procissi, D., Larson, A. C., Paunesku, T., & Woloschak, G. E. (2016). Distribution of Iron Oxide Core-Titanium Dioxide Shell Nanoparticles in VX2 Tumor Bearing Rabbits Introduced by Two Different Delivery Modalities. Nanomaterials (Basel, Switzerland), 6(8), . https://doi.org/10.3390/nano6080143
Refaat, Tamer, et al. "Distribution of Iron Oxide Core-Titanium Dioxide Shell Nanoparticles in VX2 Tumor Bearing Rabbits Introduced by Two Different Delivery Modalities." Nanomaterials (Basel, Switzerland) vol. 6,8 (2016). doi: https://doi.org/10.3390/nano6080143
Refaat T, West D, El Achy S, Parimi V, May J, Xin L, Harris KR, Liu W, Wanzer MB, Finney L, Maxey E, Vogt S, Omary RA, Procissi D, Larson AC, Paunesku T, Woloschak GE. Distribution of Iron Oxide Core-Titanium Dioxide Shell Nanoparticles in VX2 Tumor Bearing Rabbits Introduced by Two Different Delivery Modalities. Nanomaterials (Basel). 2016 Aug 03;6(8). doi: 10.3390/nano6080143. PMID: 28335271; PMCID: PMC5224625.
Copy Download .nbib Format: NLM
Share it on

Nanomaterials (Basel). 2016 Aug 03;6(8). doi: 10.3390/nano6080143.

Distribution of Iron Oxide Core-Titanium Dioxide Shell Nanoparticles in VX2 Tumor Bearing Rabbits Introduced by Two Different Delivery Modalities.

Nanomaterials (Basel, Switzerland)

Tamer Refaat, Derek West, Samar El Achy, Vamsi Parimi, Jasmine May, Lun Xin, Kathleen R Harris, William Liu, Michael Beau Wanzer, Lydia Finney, Evan Maxey, Stefan Vogt, Reed A Omary, Daniele Procissi, Andrew C Larson, Tatjana Paunesku, Gayle E Woloschak

Affiliations

  1. Radiation Oncology Department, Radiology Department and Pathology Core Facility, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA. [email protected].
  2. Clinical Oncology Department and Pathology Department, Faculty of Medicine, Alexandria University, Alexandria 21131, Egypt. [email protected].
  3. Radiation Oncology Department, Radiology Department and Pathology Core Facility, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA. [email protected].
  4. Clinical Oncology Department and Pathology Department, Faculty of Medicine, Alexandria University, Alexandria 21131, Egypt. [email protected].
  5. Radiation Oncology Department, Radiology Department and Pathology Core Facility, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA. [email protected].
  6. Radiation Oncology Department, Radiology Department and Pathology Core Facility, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA. [email protected].
  7. Radiation Oncology Department, Radiology Department and Pathology Core Facility, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA. [email protected].
  8. Radiation Oncology Department, Radiology Department and Pathology Core Facility, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA. [email protected].
  9. Radiation Oncology Department, Radiology Department and Pathology Core Facility, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA. [email protected].
  10. Radiation Oncology Department, Radiology Department and Pathology Core Facility, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA. [email protected].
  11. X-ray Sciences Division, Advanced Photon Source, Argonne National Laboratory, Argonne, IL 60439, USA. [email protected].
  12. X-ray Sciences Division, Advanced Photon Source, Argonne National Laboratory, Argonne, IL 60439, USA. [email protected].
  13. X-ray Sciences Division, Advanced Photon Source, Argonne National Laboratory, Argonne, IL 60439, USA. [email protected].
  14. Department of Radiology and Radiological Sciences, Vanderbilt University School of Medicine, Nashville, TN 37232, USA. [email protected].
  15. Radiation Oncology Department, Radiology Department and Pathology Core Facility, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA. [email protected].
  16. Radiation Oncology Department, Radiology Department and Pathology Core Facility, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA. [email protected].
  17. Radiation Oncology Department, Radiology Department and Pathology Core Facility, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA. [email protected].
  18. Radiation Oncology Department, Radiology Department and Pathology Core Facility, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA. [email protected].

PMID: 28335271 PMCID: PMC5224625 DOI: 10.3390/nano6080143

Abstract

This work compares intravenous (IV) versus fluoroscopy-guided transarterial intra-catheter (IC) delivery of iron oxide core-titanium dioxide shell nanoparticles (NPs) in vivo in VX2 model of liver cancer in rabbits. NPs coated with glucose and decorated with a peptide sequence from cortactin were administered to animals with developed VX2 liver cancer. Two hours after NPs delivery tumors, normal liver, kidney, lung and spleen tissues were harvested and used for a series on histological and elemental analysis tests. Quantification of NPs in tissues was done both by bulk inductively coupled plasma mass spectrometry (ICP-MS) analysis and by hard X-ray fluorescence microscopy. Both IV and IC NPs injection are feasible modalities for delivering NPs to VX2 liver tumors with comparable tumor accumulation. It is possible that this is an outcome of the fact that VX2 tumors are highly vascularized and hemorrhagic, and therefore enhanced permeability and retention (EPR) plays the most significant role in accumulation of nanoparticles in tumor tissue. It is, however, interesting to note that IV delivery led to increased sequestration of NPs by spleen and normal liver tissue, while IC delivery lead to more NP positive Kupffer cells. This difference is most likely a direct outcome of blood flow dynamics. Armed with this knowledge about nanoparticle delivery, we plan to test them as radiosensitizers in the future.

Keywords: core–shell nanoparticle; rabbit VX2 liver cancer model; transarterial intra-catheter delivery

References

  1. Nanomedicine. 2013 Oct;9(7):961-71 - PubMed
  2. Nat Rev Cancer. 2014 Jan;14(1):39-48 - PubMed
  3. J Vasc Interv Radiol. 2007 Oct;18(10 ):1280-6 - PubMed
  4. Health Phys. 2012 Aug;103(2):181-6 - PubMed
  5. Anal Biochem. 2008 Dec 15;383(2):226-35 - PubMed
  6. CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 - PubMed
  7. Nanomedicine. 2008 Sep;4(3):201-7 - PubMed
  8. Nanoscale. 2013 Dec 7;5(23):11394-9 - PubMed
  9. J Natl Cancer Inst. 2011 Nov 16;103(22):1656-64 - PubMed
  10. ACS Nano. 2013 Dec 23;7(12):10502-17 - PubMed
  11. J Magn Reson Imaging. 2006 Jul;24(1):242-7 - PubMed
  12. Radiology. 2007 Oct;245(1):130-9 - PubMed
  13. Cancer Res. 2012 Feb 1;72(3):769-78 - PubMed
  14. Nat Mater. 2003 May;2(5):343-6 - PubMed
  15. Nano. 2008 Feb 1;3(1):27-36 - PubMed
  16. J Magn Reson Imaging. 2009 Aug;30(2):366-73 - PubMed
  17. Proc Natl Acad Sci U S A. 2007 Oct 30;104(44):17412-7 - PubMed
  18. J Am Chem Soc. 2007 Dec 26;129(51):15760-1 - PubMed
  19. Nano Lett. 2007 Mar;7(3):596-601 - PubMed
  20. Biol Pharm Bull. 1994 Sep;17(9):1251-5 - PubMed
  21. World J Radiol. 2012 Sep 28;4(9):405-12 - PubMed
  22. Nanomedicine. 2011 Apr;7(2):123-30 - PubMed
  23. J Vasc Interv Radiol. 2008 Jun;19(6):931-6 - PubMed
  24. Oncotarget. 2011 Dec;2(12):1352-67 - PubMed
  25. Radiology. 2008 Dec;249(3):845-54 - PubMed
  26. Acad Radiol. 2005 Oct;12(10):1342-50 - PubMed
  27. Small. 2009 Jun;5(11):1318-25 - PubMed

Publication Types

Grant support